Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: A 15-year follow up

Journal of Internal Medicine

Volumn 260, Issue 3, 2006, Pages 272-280

  Stettler, C ^a   Suter, Y ^a   Allemann, S ^a   Zwahlen, M ^a   Christ, E R ^a   Diem, P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Apolipoproteins; Cardiovascular risk factors; Mortality; Type 1 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B;

ADULT; ARTICLE; AUTOPSY; CARDIOVASCULAR RISK; CAUSE OF DEATH; DEATH CERTIFICATE; FEMALE; FOLLOW UP; GENDER; HEART DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; PREDICTION; PRIORITY JOURNAL;

APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 33747447677     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01690.x     Document Type: Article

References (49)

1. Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006; 259: 247-58.
2. Faergeman O. Introduction: apolipoproteins and guidelines for prevention of cardiovascular disease. J Intern Med 2006; 259: 434-6.
3. Charlton-Menys V, Durrington P. Apolipoproteins AI and B as therapeutic targets. J Intern Med 2006; 259: 462-72.
4. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 2006; 259: 437-46.
5. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
6. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
7. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.
8. Erhardt LR, Gotto A Jr. The evolution of European guidelines: changing the management of cholesterol levels. Atherosclerosis 2006; 185: 12-20.
9. St-Pierre AC, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 553-9.
10. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 3375-83.
11. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294: 326-33.
12. Shai I, Rimm EB, Hankinson SE et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 2004; 110: 2824-30.
13. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
14. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006; 259: 481-92.
15. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 2006; 26: 406-10.
16. Al-Bahrani AI, Bakhiet CS, Bayoumi RA, Al-Yahyaee SA. A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia. Diabetes Res Clin Pract 2005; 69: 44-51.
17. Sattar N, Williams K, Sniderman AD, D'Agostino R Jr, Haffner SM. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 2004; 110: 2687-93.
18. Wagner AM, Perez A, Zapico E, Ordonez-Llanos J. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care 2003; 26: 2048-51.
19. Sniderman AD, Lamarche B, Tilley J, Seccombe D, Frohlich J. Hypertriglyceridemic hyperapoB in type 2 diabetes. Diabetes Care 2002; 25: 579-82.
20. Bruno G, Merletti F, Biggeri A et al. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study. Diabetologia 2006; 49: 937-44.
21. Schulze MB, Shai I, Manson JE et al. Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes. Diabetologia 2004; 47: 2129-36.
22. Jiang R, Schulze MB, Li T et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004; 27: 1991-7.
23. Corsetti JP, Zareba W, Moss AJ, Sparks CE. Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis 2004; 177: 367-73.
24. Daneman D. Type 1 diabetes. Lancet 2006; 367: 847-58.
25. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. Diabetologia 2006; 49: 660-6.
26. Duvillard L, Florentin E, Lalanne-Mistrich ML et al. Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men. Diabetologia 2005; 48: 1366-72.
27. Christ ER, Carroll PV, Albany E et al. Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. Clin Endocrinol (Oxf) 2001; 55: 777-87.
28. Chaturvedi N, Fuller JH, Taskinen MR. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 2001; 24: 2071-7.
29. Jenkins AJ, Lyons TJ, Zheng D et al. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 2003; 64: 817-28.
30. Lyons TJ, Jenkins AJ, Zheng D et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-8.
31. Weis U, Turner B, Gibney J et al. Long-term predictors of coronary artery disease and mortality in type 1 diabetes. QJM 2001; 94: 623-30.
32. Teuscher A, Herman JB, Studer PP. Vascular diseases in 534 Swiss diabetics within the scope of a multinational study. Klin Wochenschr 1983; 61: 139-49.
33. Jarrett RJ, Keen H, Grabauskas V. The WHO multinational study of vascular disease in diabetes: 1. General description. Diabetes Care 1979; 2: 175-86.
34. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis: Part II. Multivariate data analysis - an introduction to concepts and methods. Br J Cancer 2003; 89: 431-6.
35. Lopes-Virella MF, McHenry MB, Lipsitz S et al. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2006; Epub ahead of print.
36. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002; 22: 1918-23.
37. Diem P, Deplazes M, Fajfr R et al. Effects of alcohol consumption on mortality in patients with type 2 diabetes mellitus. Diabetologia 2003; 46: 1581-5.
38. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-31.
39. Stettler C, Allemann S, Jüni P et al. Glycemic control and macrovascular disease in type 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006; 152: 27-38.
40. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447-59.
41. Sniderman AD, Furberg CD, Keech A et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777-80.
42. James RW, Pometta D. Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes 1990; 39: 1158-64.
43. Pedersen TR, Olsson AG, Faergeman O et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-60.
44. Simes RJ, Marschner IC, Hunt D et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002; 105: 1162-9.
45. Gotto AM Jr, Whitney E, Stein EA et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477-84.
46. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
47. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
48. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003; 169: 921-4.
49. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002; 106: 2526-9.